Supernus Pharmaceuticals, Inc.
SUPN
$50.36
$0.450.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 718.95M | 681.54M | 665.13M | 668.00M | 661.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 718.95M | 681.54M | 665.13M | 668.00M | 661.82M |
| Cost of Revenue | 25.52M | 26.87M | 25.16M | 26.25M | 26.79M |
| Gross Profit | 693.43M | 654.67M | 639.97M | 641.75M | 635.02M |
| SG&A Expenses | 497.23M | 381.48M | 351.76M | 343.11M | 335.28M |
| Depreciation & Amortization | 89.46M | 83.17M | 78.34M | 77.63M | 77.98M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 767.48M | 649.36M | 613.09M | 608.89M | 599.96M |
| Operating Income | -48.53M | 32.18M | 52.04M | 59.11M | 61.86M |
| Income Before Tax | -49.03M | -20.73M | 82.16M | 91.80M | 97.87M |
| Income Tax Expenses | -10.48M | -1.62M | 17.67M | 29.88M | 24.01M |
| Earnings from Continuing Operations | -38.55 | -19.12 | 64.50 | 61.91 | 73.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.55M | -19.12M | 64.50M | 61.91M | 73.87M |
| EBIT | -48.53M | 32.18M | 52.04M | 59.11M | 61.86M |
| EBITDA | 43.03M | 117.57M | 132.72M | 139.16M | 142.27M |
| EPS Basic | -0.68 | -0.33 | 1.16 | 1.12 | 1.34 |
| Normalized Basic EPS | -0.37 | 0.54 | 0.79 | 0.86 | 0.88 |
| EPS Diluted | -0.68 | -0.34 | 1.15 | 1.11 | 1.32 |
| Normalized Diluted EPS | -0.38 | 0.53 | 0.78 | 0.85 | 0.87 |
| Average Basic Shares Outstanding | 225.79M | 223.91M | 222.50M | 221.46M | 220.40M |
| Average Diluted Shares Outstanding | 226.40M | 225.53M | 224.99M | 224.07M | 223.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |